FY2025 · period end Dec '25 · from the 10-K filed Feb 13, 2026
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $8.75B | $9.38B | $9.21B | $10.58B | $10.48B |
| Gross Profit | $1.84B | $2.29B | $2.06B | $2.14B | $2.50B |
| Operating Income | — | — | — | — | — |
| Net Income | $0.47B | $0.91B | $0.89B | $0.79B | $0.86B |
| EPS (Diluted) | $4.10 | $7.67 | $7.49 | $6.35 | $6.25 |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $14.86B | $15.21B | $14.63B | $14.67B | $15.52B |
| Total Liabilities | $8.82B | $9.36B | $9.10B | $9.43B | $9.73B |
| Stockholders' Equity | $6.04B | $5.85B | $5.53B | $5.24B | $5.79B |
| Cash & Equivalents | $0.57B | $0.84B | $0.55B | $0.49B | $0.46B |
| Total Debt | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | $0.97B | $1.29B | $1.37B | $0.97B | $1.62B |
| Capital Expenditures | $0.55B | $0.60B | $0.83B | $0.61B | $0.56B |
| Free Cash Flow | $0.42B | $0.69B | $0.55B | $0.36B | $1.06B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | 21.1% | 24.4% | 22.4% | 20.2% | 23.9% |
| Operating Margin | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% |
| Net Margin | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% |
| Return on Equity | 8.0% | 15.9% | 16.6% | 14.4% | 14.4% |
| Return on Assets | 3.2% | 6.1% | 6.1% | 5.3% | 5.4% |
| Debt / Equity | 0.79× | 0.86× | 0.88× | 0.98× | 0.89× |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 10-Q | 0000915389-26-000141 | Jun 30, 2026 | Jul 31, 2026 | Jul 31, 2026 15:10 UTC | EDGAR |
| 8-K | 0000915389-26-000138 | Jul 30, 2026 | Jul 30, 2026 | Jul 30, 2026 20:17 UTC | EDGAR |
| 8-K | 0000915389-26-000123 | May 7, 2026 | May 12, 2026 | May 12, 2026 20:05 UTC | EDGAR |
| 10-Q | 0000915389-26-000099 | Mar 31, 2026 | May 1, 2026 | May 1, 2026 15:58 UTC | EDGAR |
| 8-K | 0000915389-26-000094 | Apr 30, 2026 | Apr 30, 2026 | Apr 30, 2026 20:17 UTC | EDGAR |
| 8-K | 0001193125-26-061351 | Feb 20, 2026 | Feb 20, 2026 | Feb 20, 2026 21:10 UTC | EDGAR |
| 10-K | 0000915389-26-000013 | Dec 31, 2025 | Feb 13, 2026 | Feb 13, 2026 16:58 UTC | EDGAR |
| 8-K | 0000915389-26-000006 | Jan 29, 2026 | Jan 29, 2026 | Jan 29, 2026 21:16 UTC | EDGAR |
Direct links to SEC EDGAR. EMN has additional filings available on the SEC site.
6 numbers EASTMAN CHEMICAL CO later changed — same XBRL tag, both filings linked.
Net Income (Loss) Attributable to Parent·3 months to Dec 2011
Major restatementwas$100M
Revised down in a 10-K. Any P/E built on the original was 733.3% too low.
Gross Profit·3 months to Dec 2011
Major restatementwas$324M
Revised down in a 10-K.
Net Income (Loss) Attributable to Parent·FY 2009
Major restatementwas$136M
Revised down in a 8-K. Any P/E built on the original was 52.8% too low.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·FY 2009
Major restatementwas$254M
Revised down in a 8-K.
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest·FY 2009
Major restatementwas$226M
Revised down in a 8-K.
Operating Income (Loss)·FY 2009
Major restatementwas$317M
Revised down in a 8-K.
EMN is not the only one.
See every restatement we've found across the market — or get an alert the next time EMN revises a number.
Restatements are detected by comparing every vintage of a fact across all of EASTMAN CHEMICAL CO's filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows EMN's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling EASTMAN CHEMICAL CO — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on EMN yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on EMN and publish the result to your public profile.
Ask about EASTMAN CHEMICAL CO
Continue in Workspace — cited answers on EMN, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs